CD3-specific antibodies: a portal to the treatment of autoimmunity - PubMed (original) (raw)

Review

doi: 10.1038/nri2134. Epub 2007 Jul 20.

Affiliations

Review

CD3-specific antibodies: a portal to the treatment of autoimmunity

Lucienne Chatenoud et al. Nat Rev Immunol. 2007 Aug.

Abstract

Targeted immunotherapies hold great promise for the treatment and cure of autoimmune diseases. The efficacy of CD3-specific monoclonal antibody therapy in mice and humans stems from its ability to re-establish immune homeostasis in treated individuals. This occurs through modulation of the T-cell receptor (TCR)-CD3 complex (also termed antigenic modulation) and/or induction of apoptosis of activated autoreactive T cells, which leaves behind 'space' for homeostatic reconstitution that favours selective induction, survival and expansion of adaptive regulatory T cells, which establishes long-term tolerance. This Review summarizes the pre-clinical and clinical studies of CD3-specific monoclonal antibody therapy and highlights future opportunities to enhance the efficacy of this potent immunotherapeutic.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources